Stifel Financial Corp Invests $327,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Stifel Financial Corp bought a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the third quarter, Holdings Channel reports. The institutional investor bought 16,976 shares of the company’s stock, valued at approximately $327,000.

Several other hedge funds also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its position in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth $27,000. Values First Advisors Inc. purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at about $30,000. nVerses Capital LLC bought a new position in shares of Syndax Pharmaceuticals during the second quarter valued at about $33,000. Finally, Inspire Investing LLC boosted its holdings in Syndax Pharmaceuticals by 15.0% during the second quarter. Inspire Investing LLC now owns 17,290 shares of the company’s stock worth $355,000 after purchasing an additional 2,258 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on SNDX shares. Citigroup increased their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, November 21st. The Goldman Sachs Group boosted their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. UBS Group assumed coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price for the company. Finally, StockNews.com downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.90.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ SNDX opened at $12.77 on Friday. The business’s fifty day moving average price is $16.62 and its 200-day moving average price is $19.02. Syndax Pharmaceuticals, Inc. has a one year low of $12.52 and a one year high of $25.34. The stock has a market capitalization of $1.09 billion, a PE ratio of -3.52 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the prior year, the business earned ($0.73) EPS. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).